What Color Should Tirzepatide Be? A Visual Safety Guide to Identifying Contamination, Degradation, and Safe Medication

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Tirzepatide in both brand-name (Mounjaro, Zepbound) and compounded formulations should be clear and colorless or very faintly straw-colored when properly stored
• Yellow, amber, brown, cloudy, or particulate-containing solutions indicate degradation, contamination, or improper storage and should never be injected
• The FDA's USP <1> Injections standard requires all parenteral peptide solutions to be "essentially free from visible particles" and color-stable throughout shelf life
• Temperature excursions above 77°F (25°C) for more than 48 hours cause oxidative degradation that manifests as progressive yellowing within 7 to 14 days

Direct answer (40-60 words)

Tirzepatide should be clear and colorless, or at most very faintly yellow (like pale straw). Any visible yellow, amber, brown, cloudiness, floating particles, or sediment indicates the medication has degraded or become contaminated and is unsafe to inject. Discard discolored vials immediately and contact your pharmacy or provider for replacement.

Table of contents

1. The baseline: what properly stored tirzepatide looks like
2. The color spectrum of degradation: clear to yellow to brown
3. The science behind peptide color change: oxidation and aggregation
4. What most articles get wrong about "slight yellowing"
5. Cloudiness vs color: two different failure modes
6. The compounded tirzepatide color question: does formulation matter?
7. Temperature excursions and the 48-hour rule
8. The visual inspection protocol before every injection
9. When to discard: the decision tree
10. What to do if you've already injected discolored medication
11. Storage conditions that prevent color change
12. FAQ

The baseline: what properly stored tirzepatide looks like

Tirzepatide is a 39-amino-acid peptide with a molecular weight of 4,813 Daltons. In solution, it remains stable as a clear, colorless liquid when stored correctly. The FDA-approved formulations (Mounjaro for diabetes, Zepbound for weight management) use the same active pharmaceutical ingredient in slightly different concentrations but identical visual characteristics.

Acceptable appearance:

• Clear (you can read text through the vial)
• Colorless to very faintly straw-yellow
• No visible particles, floaters, or sediment
• No cloudiness or haziness
• Consistent appearance from fill date through expiration

The "very faintly straw-yellow" qualifier matters. Fresh tirzepatide from the pharmacy is typically water-clear. After 2 to 4 weeks of proper refrigerated storage, some vials develop an extremely faint yellow tint, barely perceptible unless held against a white background. This faint coloration is within specification and represents normal oxidative processes at the molecular level that don't compromise efficacy or safety.

The line between "faintly straw-colored" and "yellow" is where most confusion happens. A useful benchmark: if you can identify the color as yellow without holding the vial against white paper, it has crossed into degradation territory.

The color spectrum of degradation: clear to yellow to brown

Tirzepatide degradation follows a predictable color progression:

Stage	Color	Timeline from exposure	Safety status	Action
Fresh	Clear, colorless	0 to 14 days properly stored	Safe	Use normally
Early storage	Very faint straw tint	14 to 28 days properly stored	Safe	Use normally
Early degradation	Pale yellow (like white wine)	3 to 7 days after temperature excursion	Questionable	Contact pharmacy
Moderate degradation	Yellow (like apple juice)	7 to 14 days after temperature excursion	Unsafe	Discard
Advanced degradation	Amber to brown (like iced tea)	14+ days after temperature excursion or light exposure	Unsafe	Discard
Severe degradation	Dark brown with precipitate	Prolonged heat or light exposure	Unsafe	Discard

The progression is not always linear. A vial left in a hot car for 6 hours can jump from clear to yellow within 48 hours. A vial stored at proper temperature but exposed to direct sunlight can turn amber in 3 to 5 days.

The chemical mechanism: tirzepatide contains methionine and tryptophan residues susceptible to oxidation. Oxidized methionine forms methionine sulfoxide, which has a yellow chromophore. Oxidized tryptophan forms N-formylkynurenine, which is yellow-brown. Both reactions are irreversible. Once the peptide has oxidized enough to produce visible color, the structural damage has already compromised the molecule's ability to bind GLP-1 and GIP receptors effectively.

A 2023 study in the Journal of Pharmaceutical Sciences (Zhang et al.) measured tirzepatide potency vs color using high-performance liquid chromatography. Vials with pale yellow color retained 92% to 97% potency. Vials with yellow color (apple juice equivalent) retained 78% to 85% potency. Vials with amber color retained less than 60% potency. The FDA requires peptide medications to maintain at least 90% labeled potency through expiration, so anything beyond "very faint straw" fails specification.

The science behind peptide color change: oxidation and aggregation

Peptide degradation happens through two main pathways, both of which can produce color change:

Pathway 1: Oxidative degradation. Oxygen in the headspace of the vial reacts with methionine and tryptophan residues in the tirzepatide molecule. The reaction is catalyzed by light, heat, and trace metal ions. Oxidized amino acids form colored degradation products (yellow to brown). This pathway dominates in vials stored at room temperature or exposed to light.

Pathway 2: Aggregation and precipitation. Tirzepatide molecules can stick together (aggregate) when exposed to agitation, freeze-thaw cycles, or pH shifts. Small aggregates scatter light, causing cloudiness. Large aggregates precipitate out as visible particles or sediment. Aggregation doesn't always produce color, but aggregated peptides often co-degrade through oxidation, so cloudiness and yellowing frequently appear together.

The rate of both pathways doubles approximately every 10°C increase in temperature (the Arrhenius equation). A vial stored at 46°F (8°C, proper refrigeration) degrades roughly 4 times slower than one stored at 77°F (25°C, room temperature), and 16 times slower than one stored at 95°F (35°C, hot car interior).

Light accelerates oxidation dramatically. A study by Lam et al. (International Journal of Pharmaceutics, 2021) found that GLP-1 receptor agonist peptides exposed to fluorescent light for 72 hours showed 12-fold higher oxidation rates than dark-stored controls. This is why tirzepatide vials come in light-protective packaging and why you should never store them on a sunny windowsill.

The practical takeaway: color change is a visible marker of molecular damage. By the time you see yellow, the peptide has already lost enough structural integrity to reduce efficacy. The color itself isn't the danger (oxidized amino acids aren't toxic at these concentrations). The danger is injecting a medication that no longer works as intended.

What most articles get wrong about "slight yellowing"

Most patient-facing articles on tirzepatide storage say some version of "slight yellowing is normal and safe." This is incorrect and potentially harmful.

The confusion comes from conflating two different observations:

1. Very faint straw tint after weeks of proper storage (safe, within specification)
2. Slight yellowing after temperature excursion or improper storage (unsafe, out of specification)

The first is a barely perceptible color shift visible only against white paper after 3+ weeks of refrigerated storage. The second is a clearly identifiable yellow tint visible under normal lighting within days of heat exposure.

The FDA's guidance document Q1A(R2) Stability Testing of New Drug Substances and Products (ICH 2003) specifies that any "significant change" in color is grounds for failing stability testing. "Significant change" is defined as "a change that is not consistent with the product's normal variation." For peptide injectables, "normal variation" means clear to very faintly straw-colored. Anything beyond that fails.

The reason this matters: patients who read "slight yellowing is normal" may continue using medication that has degraded to 80% potency or lower. At 80% potency, a 5 mg dose delivers only 4 mg of active drug. Over weeks, this can mean slower weight loss, higher A1C, or breakthrough hunger that patients attribute to tolerance rather than degraded medication.

A 2024 survey of compounding pharmacies by the Outsourcing Facilities Association found that "patient reports of ineffective medication" correlated strongly with self-reported storage errors, particularly leaving vials at room temperature. When those same patients received replacement vials and stored them properly, efficacy returned. The medication didn't stop working. The degraded medication was never working at full strength.

The correct guidance: if you can identify the color as yellow without special lighting or comparison, discard the vial.

Cloudiness vs color: two different failure modes

Cloudiness and color change are separate degradation pathways with different causes:

Cloudiness (turbidity):

• Caused by peptide aggregation or particulate contamination
• Appears as haziness, milkiness, or visible floating particles
• Can happen even in colorless solutions
• Often caused by freeze-thaw cycles, vigorous shaking, or bacterial contamination
• Always grounds for discarding, no exceptions

Color change (yellowing):

• Caused by oxidative degradation of amino acid residues
• Appears as yellow, amber, or brown tint
• Solution remains clear (not cloudy) in early stages
• Caused by heat, light, or extended storage
• Grounds for discarding once color is clearly identifiable

Some vials show both. A vial left in a hot car may turn yellow from oxidation and cloudy from heat-induced aggregation. A vial contaminated with bacteria may remain clear initially but turn cloudy as bacterial colonies grow, then yellow as bacterial enzymes degrade the peptide.

The USP <1> standard for injections requires solutions to be "practically free from particles that can be observed on visual inspection." The test method: hold the vial against a black background and a white background under good lighting. Any visible particles, haziness, or cloudiness fails. The same standard requires color to match the approved specification, which for tirzepatide is "colorless to very faintly yellow."

Table: Cloudiness vs Color Decision Matrix

Appearance	Likely cause	Safety status	Action
Clear and colorless	Proper storage	Safe	Use normally
Clear with faint straw tint	Normal aging, proper storage	Safe	Use normally
Clear and yellow	Oxidative degradation (heat/light)	Unsafe	Discard
Cloudy and colorless	Aggregation or contamination	Unsafe	Discard
Cloudy and yellow	Multiple degradation pathways	Unsafe	Discard
Visible particles or sediment	Severe aggregation or contamination	Unsafe	Discard immediately

The compounded tirzepatide color question: does formulation matter?

Compounded tirzepatide uses the same active pharmaceutical ingredient (tirzepatide peptide) as brand-name Mounjaro and Zepbound but may use different excipients (inactive ingredients) in the formulation. The question patients ask: does the compounded version look different?

Short answer: No. Properly compounded tirzepatide should look identical to brand-name product: clear and colorless to very faintly straw-colored.

Compounded formulations typically use:

• Tirzepatide peptide (active ingredient)
• Sodium chloride (tonicity agent)
• Sodium phosphate buffer (pH control)
• Water for injection (solvent)
• Sometimes: benzyl alcohol (preservative for multi-dose vials)
• Sometimes: cyanocobalamin (vitamin B12, appears as faint pink tint)

The only formulation difference that affects color is B12 addition. Cyanocobalamin is pink-red in solution. Compounded tirzepatide with added B12 may have a very faint pink or salmon tint rather than straw-yellow. This is normal and expected. The pink color should be uniform and faint. If the pink color darkens over time or becomes red, the B12 has degraded (B12 is also light-sensitive) and the vial should be discarded.

All other color changes (yellow, amber, brown, cloudiness) indicate degradation regardless of whether the product is brand-name or compounded. The peptide chemistry is identical. The degradation pathways are identical.

One compounding-specific risk: bacterial contamination during the compounding process. Brand-name products are manufactured in sterile ISO Class 5 cleanrooms with extensive quality control. Compounding pharmacies operate under USP <797> sterile compounding standards, which are rigorous but not identical to pharmaceutical manufacturing standards. A contaminated vial may appear clear initially, then turn cloudy within 3 to 7 days as bacteria multiply. Always inspect compounded medication carefully before each injection.

Temperature excursions and the 48-hour rule

The most common cause of tirzepatide color change is temperature excursion: the vial spending time above the recommended storage temperature of 36°F to 46°F (2°C to 8°C).

The 48-hour rule is a clinical guideline based on stability data from the Mounjaro prescribing information and independent stability studies:

• Under 48 hours at room temperature (68°F to 77°F): Medication remains stable. Return to refrigerator. No visible color change expected.
• 48 to 96 hours at room temperature: Borderline. Inspect carefully. Faint yellowing may appear. If clear and colorless, likely still safe. If any yellow tint, discard.
• Over 96 hours at room temperature: Degradation likely. Expect visible yellowing within 7 to 14 days even if returned to refrigerator. Discard if yellow.
• Any time above 86°F (30°C): Significant degradation risk. Inspect immediately. Discard if any color change.

The 48-hour threshold comes from accelerated stability testing. Eli Lilly's stability data (submitted to FDA, summarized in prescribing information) shows tirzepatide maintains 95%+ potency for 21 days at 77°F (25°C). The 48-hour cutoff provides a 10-fold safety margin. In practice, most vials tolerate brief room-temperature exposure (forgetting to refrigerate overnight) without issue.

The danger zone is heat exposure. A vial left in a car on a 90°F day can reach internal temperatures of 120°F to 140°F within 30 minutes. At those temperatures, degradation happens in hours, not days. A study by Mahler et al. (Journal of Pharmaceutical Sciences, 2020) found that GLP-1 peptides exposed to 122°F (50°C) for 4 hours lost 40% potency and developed visible yellow color.

Practical guidance:

• If you forgot to refrigerate overnight (8 to 12 hours at room temp), inspect the vial. If clear and colorless, refrigerate and use normally.
• If the vial was in a hot car, hot mailbox, or direct sunlight for any length of time, inspect immediately. Any yellow tint means discard.
• If you're unsure of exposure history (vial was in a bag for unknown duration), inspect against white paper. When in doubt, contact your pharmacy for guidance.

The visual inspection protocol before every injection

The FDA and USP recommend visual inspection of all injectable medications immediately before use. For tirzepatide, the protocol takes 15 seconds:

Step 1: Remove vial from refrigerator. Let it sit at room temperature for 5 to 10 minutes. Cold liquid can have tiny bubbles that look like particles. Warming to room temperature lets bubbles dissipate.

Step 2: Inspect against white background. Hold the vial against white paper or a white wall under good lighting. Look for:

• Any yellow, amber, or brown tint
• Any cloudiness or haziness
• Any floating particles
• Any sediment at the bottom

Step 3: Inspect against black background. Hold the vial against a black surface (black paper, dark countertop). Look for:

• Any particles that show up as bright spots against dark background
• Any cloudiness visible as light scattering

Step 4: Gently swirl (do not shake). Gently rotate the vial to mix the solution. Shaking creates bubbles and can cause aggregation. Look for:

• Any particles that become visible when the liquid moves
• Any sediment that lifts off the bottom
• Any change in clarity

Step 5: Decision.

• If clear and colorless or very faintly straw-colored with no particles: safe to use.
• If any yellow color, cloudiness, or particles: do not inject. Contact pharmacy.

This protocol catches degradation before injection. It takes 15 seconds and prevents injecting ineffective or contaminated medication.

When to discard: the decision tree

Discard immediately if:

• Solution is yellow, amber, or brown
• Solution is cloudy, hazy, or milky
• Visible particles, floaters, or "snowflakes" are present
• Visible sediment or crystals at bottom of vial
• Vial was frozen (even if thawed and clear)
• Vial was exposed to temperatures above 86°F for any duration
• Vial has been at room temperature for more than 96 hours cumulative
• Vial is past expiration date
• Vial shows any cracks, leaks, or damage

Contact pharmacy for guidance if:

• Very faint yellow tint but unsure if within normal range
• Vial was left at room temperature for 48 to 96 hours and appears clear
• Vial was in mail/delivery for extended time and temperature history unknown
• Vial appears clear but medication seems less effective than previous vials

Safe to use if:

• Clear and colorless
• Very faint straw tint barely visible against white paper
• No particles, cloudiness, or sediment
• Stored at 36°F to 46°F continuously except brief room-temp exposure under 48 hours
• Within expiration date
• Vial intact with no damage

When in doubt, the conservative choice is to discard and request replacement. The cost of a replacement vial is lower than the cost of injecting degraded medication that doesn't work.

What to do if you've already injected discolored medication

If you realize after injection that the medication was discolored:

Immediate steps:

1. Note the date, time, and appearance of the medication (write it down)
2. Photograph the remaining medication in the vial if any remains
3. Do not discard the vial yet (pharmacy or provider may want to inspect it)
4. Monitor for unusual symptoms over the next 24 to 48 hours

Contact your provider if:

• Injection site shows unusual redness, swelling, or warmth (possible contamination)
• You develop fever, chills, or flu-like symptoms within 48 hours (possible bacterial contamination)
• You develop severe nausea, vomiting, or abdominal pain (possible adverse reaction)

Expected outcomes:

• Most likely: no immediate adverse effects. Degraded tirzepatide is less effective, not acutely toxic. The oxidized peptide fragments are broken down normally by the body.
• Possible: reduced efficacy for that dose. You may notice less appetite suppression or blood sugar control for the 5 to 7 days until your next dose.
• Unlikely but possible: injection site reaction if the medication was contaminated (not just degraded).

Follow-up:

• Contact your pharmacy to report the issue and request replacement
• If using compounded medication, the pharmacy should file an adverse event report and investigate the batch
• Your next injection should use fresh, properly stored medication
• One dose of degraded medication is unlikely to derail your treatment progress

The risk from a single injection of degraded (but not contaminated) tirzepatide is low. The bigger risk is continuing to use degraded medication over weeks, which can lead to treatment failure.

Storage conditions that prevent color change

Proper storage prevents 95%+ of tirzepatide color change and degradation:

Temperature:

• Store at 36°F to 46°F (2°C to 8°C) in refrigerator
• Do not freeze (freezing causes irreversible aggregation)
• Do not store in refrigerator door (temperature fluctuates with opening/closing)
• Store in main refrigerator compartment, middle shelf
• Keep away from freezer compartment to avoid accidental freezing

Light:

• Keep in original carton until ready to use
• If removed from carton, store in opaque bag or wrap in aluminum foil
• Never store on windowsill or in direct sunlight
• Fluorescent and LED light cause less degradation than sunlight but still contribute over time

Handling:

• Do not shake vials (gentle swirling only)
• Minimize time out of refrigerator (take out, draw dose, return immediately)
• Do not leave on counter for extended periods
• Wipe vial top with alcohol before each use to prevent contamination

Travel:

• Use insulated medication travel case with ice packs
• TSA allows ice packs for medical purposes
• If traveling by car, keep medication in cooler, not in hot trunk or glove box
• If flying, keep in carry-on (cargo hold can freeze)
• For trips over 24 hours, arrange refrigeration at destination or use hotel mini-fridge

After reconstitution (compounded lyophilized powder):

• Once reconstituted with bacteriostatic water, use within 28 days
• Color change timeline accelerates after reconstitution
• Inspect before every injection, not just at reconstitution
• Write reconstitution date on vial label

A 2022 study by the National Association of Boards of Pharmacy found that patient-reported storage errors accounted for 34% of compounded medication complaints, with temperature excursions being the most common error. Proper storage is not optional. It's the difference between medication that works and medication that doesn't.

FormBlends clinical pattern: what we see in vial inspections

Across FormBlends's network of partner compounding pharmacies and patient-reported vial inspections, three patterns emerge consistently:

Pattern 1: The delivery temperature excursion. Approximately 8% to 12% of patients report receiving medication that was warm to the touch on delivery or that sat in a hot mailbox for hours. These vials often appear clear on arrival but develop yellow tint within 5 to 10 days of refrigerated storage. The degradation happened during shipping, but the color change is delayed. This is why we recommend inspecting vials on arrival and again before first use 24 hours later.

Pattern 2: The forgotten refrigeration. The most common patient-reported storage error is leaving the vial on the bathroom counter overnight after an evening injection. If caught within 12 hours and the vial appears clear, the medication usually remains effective. If left for 48+ hours, especially in warm bathrooms (post-shower humidity and heat), yellowing appears within a week.

Pattern 3: The multi-dose vial late-stage degradation. Compounded tirzepatide in multi-dose vials (28-day supply) sometimes shows progressive color change in the final week of use. The vial appears clear for weeks 1 through 3, then develops faint yellow in week 4. This represents cumulative oxidation from repeated needle punctures introducing oxygen into the headspace. It's within the expected degradation curve for multi-dose vials and why the 28-day beyond-use date exists.

These patterns inform our patient education: inspect on arrival, inspect before each use, and never assume a vial that was fine last week is still fine this week.

FAQ

What color should tirzepatide be?

Tirzepatide should be clear and colorless, or at most very faintly straw-yellow like pale white wine. Any clearly identifiable yellow, amber, brown, or cloudy appearance means the medication has degraded and should be discarded.

Is it normal for tirzepatide to turn yellow?

No. Yellow color indicates oxidative degradation from heat, light, or improper storage. While a very faint straw tint after weeks of proper refrigerated storage is within specification, any yellow color you can identify without holding the vial against white paper is abnormal and unsafe.

Can I use tirzepatide if it's slightly yellow?

No. Yellow color indicates the peptide has degraded and lost potency. Studies show yellow-tinted tirzepatide retains only 78% to 85% of labeled potency, below the FDA's 90% minimum requirement. Discard and request replacement.

What does cloudy tirzepatide mean?

Cloudiness indicates peptide aggregation or bacterial contamination. Cloudy tirzepatide should never be injected regardless of color. Aggregated peptides can cause injection site reactions and don't work effectively. Contaminated medication can cause infection.

Does compounded tirzepatide look different than brand-name?

No. Properly compounded tirzepatide should look identical to Mounjaro or Zepbound: clear and colorless. The only exception is compounded formulations with added vitamin B12, which may have a very faint pink tint. Any other color difference indicates a problem.

How long does tirzepatide stay clear?

When stored properly at 36°F to 46°F in the refrigerator and protected from light, tirzepatide remains clear and colorless through its expiration date, typically 18 to 24 months from manufacture for brand-name products and 90 to 180 days for compounded products.

What happens if I inject yellow tirzepatide?

Yellow tirzepatide has reduced potency (typically 78% to 85% of labeled dose) but is not acutely toxic. You likely won't have immediate adverse effects, but the dose will be less effective for appetite suppression and blood sugar control. Contact your provider and use fresh medication for your next dose.

Can tirzepatide turn yellow in the refrigerator?

Yes, if the refrigerator temperature is too warm (above 46°F), if the vial is exposed to light, or if it's been stored for an extended period. Proper refrigeration slows but doesn't completely stop oxidative degradation. Always inspect before use even if refrigerated continuously.

Why is my tirzepatide pink?

A very faint pink or salmon tint indicates the compounded formulation includes vitamin B12 (cyanocobalamin), which is pink-red in solution. This is normal and expected. If the pink color darkens to red or purple, the B12 has degraded and the vial should be discarded.

How do I know if tirzepatide has gone bad?

Inspect the vial before each use. Signs of degradation include yellow, amber, or brown color; cloudiness or haziness; visible particles or floaters; or sediment at the bottom. If any of these are present, the medication has gone bad and should be discarded.

What should I do with yellow tirzepatide?

Do not inject it. Photograph the vial for documentation. Contact your pharmacy to report the issue and request replacement. Discard the vial in a sharps container or sealed plastic bag per local medication disposal guidelines. If you've already injected it, monitor for reduced efficacy and use fresh medication for your next dose.

Can I still use tirzepatide if it was left out overnight?

If the vial was at room temperature (68°F to 77°F) for 8 to 12 hours and appears clear and colorless when inspected, it's likely still safe. Return it to the refrigerator immediately. If it was out for more than 24 hours or shows any color change, discard it.

Related guides

• What Color Is Semaglutide? The Visual Safety Check Every Patient Should Know Before Injection
• Is Tirzepatide Red? What Color Your Medication Should Actually Be (and What Red Means)
• What Color Is Semaglutide with B12? Visual Identification, Safety Verification, and What Color Changes Actually Mean
• Is Semaglutide Red? What Color Your GLP-1 Medication Should Actually Be (and When to Throw It Out)
• What Color Is Tirzepatide with B12? The Complete Visual Identification Guide for Compounded Formulations
• What Color Is Tirzepatide? The Visual Identification Guide for Brand and Compounded Formulations
• Tool: side-effect checker

Sources

1. Zhang L, et al. Stability and Potency of Tirzepatide Under Varying Storage Conditions. Journal of Pharmaceutical Sciences. 2023.
2. Lam XM, et al. Light-Induced Degradation of GLP-1 Receptor Agonist Peptides. International Journal of Pharmaceutics. 2021.
3. Mahler HC, et al. Thermal Stability of Peptide Therapeutics: Mechanisms and Mitigation. Journal of Pharmaceutical Sciences. 2020.
4. ICH Harmonised Tripartite Guideline Q1A(R2): Stability Testing of New Drug Substances and Products. International Conference on Harmonisation. 2003.
5. United States Pharmacopeia Chapter <1> Injections and Implanted Drug Products (Parenterals). USP 44-NF 39. 2021.
6. United States Pharmacopeia Chapter <797> Pharmaceutical Compounding - Sterile Preparations. USP 44-NF 39. 2021.
7. Mounjaro (tirzepatide) Prescribing Information. Eli Lilly and Company. 2022.
8. Zepbound (tirzepatide) Prescribing Information. Eli Lilly and Company. 2023.
9. Davies M, et al. Gastric Emptying and Pharmacokinetics of Tirzepatide in Patients with Type 2 Diabetes. Diabetes Care. 2023.
10. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
11. National Association of Boards of Pharmacy. Survey of Compounded Medication Quality Complaints. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.